Source comparison
Tesamorelin Ipamorelin for Visceral Fat Research: Peptide Comparison
Tesamorelin GHRH receptor agonist Pulsatile GH secretion 15.2% (monotherapy) Minimal Gold standard for VAT. FDA-approved for lipodystrophy Ipamorelin Ghrelin receptor agonist Amplifies GH pulse amplitude Not studied in isolation None Extends tesamorelin effica
This comparison does not assign a generated winner or score.
- Tesamorelin
- GHRH receptor agonist
- Pulsatile GH secretion
- 15.2% (monotherapy)
- Minimal
- Gold standard for VAT. FDA-approved for lipodystrophy
- Ipamorelin
- Ghrelin receptor agonist
- Amplifies GH pulse amplitude
- Not studied in isolation
- None
- Extends tesamorelin efficacy beyond 26 weeks
- GHRP-6
- Ghrelin receptor agonist (non-selective)
- GH secretion + appetite stimulation
- 8–12% (estimated)
- Moderate cortisol elevation
- Superseded by ipamorelin due to side effect profile
- CJC-1295
- GHRH analog (long half-life)
- Sustained GH elevation
- 10–14% (estimated)
- Effective but less selective than tesamorelin
- Sermorelin
- GHRH analog (short half-life)
- 6–9% (estimated)
- Requires multiple daily doses. Less practical
- Tesamorelin remains the only peptide with FDA approval specifically for visceral adiposity, supported by Phase 3 trial data showing durable VAT reduction without metabolic side effects. Ipamorelin's role is mechanistic synergy. Preventing the GH pulse attenuation that limits monotherapy protocols.